TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

Straetemans, Trudy; Janssen, Anke; Jansen, Koen; Doorn, Ruud; Aarts, Tineke; van Muyden, Anna D D; Simonis, Marieke; Bergboer, Judith; de Witte, Moniek; Sebestyen, Zsolt; Kuball, Jurgen

doi:https://doi.org/10.1016/j.ymthe.2019.11.030

TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

DSpace/Manakin Repository

TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

Straetemans, Trudy; Janssen, Anke; Jansen, Koen; Doorn, Ruud; Aarts, Tineke; van Muyden, Anna D D; Simonis, Marieke; Bergboer, Judith; de Witte, Moniek; Sebestyen, Zsolt; Kuball, Jurgen

(2020) Molecular Therapy, volume 28, issue 2, pp. 561 - 571

(Article)

Abstract

Straetemans and colleagues characterized αβT cells engineered to express a defined γδT cell receptor (TEG001) used in a first-in-human clinical study, with TLA in combination with NGS and qPCR. They provide a rapid strategy to evaluate the presence, integrity, and persistence of genetic information along the production chain of any ... read more

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: engineered T cells, gene therapy medicinal product, GTMP, targeted locus amplification, TEG001, TLA, vector copy number, γδT cells, Drug Discovery, Genetics, Molecular Medicine, Molecular Biology, Pharmacology, Journal Article

DOI: https://doi.org/10.1016/j.ymthe.2019.11.030

ISSN: 1525-0016

Publisher: Nature Publishing Group

(Peer reviewed)